Crocetin antagonizes parthanatos in ischemic stroke via inhibiting NOX2 and preserving mitochondrial hexokinase-I.
Parthanatos is one of the major pathways of programmed cell death in ischemic stroke characterized by DNA damage, poly (ADP-ribose) polymerases (PARP) activation, and poly (ADP-ribose) (PAR) formation. Here we demonstrate that crocetin, a natural potent antioxidant compound from Crocus sativus, antagonizes parthanatos in ischemic stroke. We reveal that mechanistically, ... crocetin inhibits NADPH oxidase 2 (NOX2) activation to reduce reactive oxygen species (ROS) and PAR production at the early stage of parthanatos. Meanwhile we demonstrate that PARylated hexokinase-I (HK-I) is a novel substrate of E3 ligase RNF146 and that crocetin interacts with HK-I to suppress RNF146-mediated HK-I degradation at the later stage of parthanatos, preventing mitochondrial dysfunction and DNA damage that ultimately trigger the irreversible cell death. Our study supports further development of crocetin as a potential drug candidate for preventing and/or treating ischemic stroke.
Mesh Terms:
Hexokinase, Humans, Ischemic Stroke, Mitochondria, NADPH Oxidase 2, Parthanatos, Poly (ADP-Ribose) Polymerase-1, Poly(ADP-ribose) Polymerases, Ribose
Hexokinase, Humans, Ischemic Stroke, Mitochondria, NADPH Oxidase 2, Parthanatos, Poly (ADP-Ribose) Polymerase-1, Poly(ADP-ribose) Polymerases, Ribose
Cell Death Dis
Date: Jan. 21, 2023
PubMed ID: 36681688
View in: Pubmed Google Scholar
Download Curated Data For This Publication
245069
Switch View:
- Interactions 2